tradingkey.logo

Scorpion Capital shorts drug developer Soleno

ReutersAug 15, 2025 1:15 PM

- Scorpion Capital disclosed a short position in Soleno Therapeutics SLNO.O on Friday, citing issues with the drug developer's recently approved treatment Vykat XR.

Shares of Soleno declined 15% in premarket trading. The company did not immediately respond to a Reuters request for comment.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

Tradingkey
KeyAI